Industry wants intervention to halt drift of R&D to US and China
European pharmaceutical companies are looking to the upcoming EU industrial strategy to reverse a multi-decade trend of biomedical R&D growing faster among the continent’s rivals, the European Federation of Pharmaceutical Industries and Associations has said.
Between 1990 and 2017, investment in pharmaceutical R&D in Europe increased over fourfold, but in the US it grew by a factor of eight, according to an Efpia survey.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.